Opening Paragraph (User Pain Point & Solution Focus):
Cell biology researchers, cancer biologists, and exosome scientists studying intracellular vesicle trafficking, secretion, and intercellular communication face a critical experimental challenge: RAB27B is a member of the Rab family of small GTPases (Ras-related proteins), which function as master regulators of vesicle trafficking, docking, and fusion. Specifically, RAB27B controls the exocytosis of secretory granules (hormones, digestive enzymes, immune mediators) and is also involved in exosome biogenesis and release, making it a key regulator of both classical secretion and extracellular vesicle-mediated communication. RAB27B dysfunction is implicated in various cancers (breast, pancreatic, melanoma) where it promotes metastasis, as well as in immune disorders and endocrine diseases. Reliable detection, localization, and quantification of RAB27B across various sample types (tissue sections, cell lysates, exosome preparations) and species (mouse, rabbit, porcine, human) requires high-specificity, well-validated antibodies suitable for multiple applications (western blotting, immunohistochemistry, immunofluorescence, immunoprecipitation, ELISA). The proven solution lies in the RAB27B antibody, available in mouse, rabbit, porcine, and human formats, recognized in immunohistochemical staining and western blotting, enabling researchers to study RAB27B expression, subcellular localization, vesicle trafficking dynamics, and involvement in exosome secretion. Growing patient base for RAB27B-associated cancers (breast cancer 2.3 million new cases annually, pancreatic cancer 500,000, melanoma 325,000), launch of novel RAB27B-targeting therapeutic strategies (small molecule inhibitors of Rab GTPases in preclinical development), increasing penetration of antibody-based research tools in cell biology and cancer research, and continuous regulation across the biopharmaceutical industry (validation standards for target engagement assays) are the key factors driving the growth of RAB27B antibody market revenue. This market research deep-dive analyzes the global RAB27B antibody market size, market share by antibody type (monoclonal vs. polyclonal), and application-specific demand drivers across immunochemistry (IHC), immunofluorescence (IF), immunoprecipitation (IP), western blot (WB), ELISA, and other protein-detection methods. Based on historical data (2021-2025) and forecast calculations (2026-2032), we deliver actionable intelligence for laboratory procurement specialists, core facility managers, cancer and cell biology researchers, and pharmaceutical R&D purchasers seeking validated, high-specificity RAB27B antibodies for vesicle trafficking and exosome research.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “RAB27B Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global RAB27B Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984515/rab27b-antibody
Market Size & Growth Trajectory (Updated with Recent Data):
The global market for RAB27B antibodies was estimated to be worth US16.5millionin2025andisprojectedtoreachUS16.5millionin2025andisprojectedtoreachUS 25.8 million by 2032, growing at a CAGR of 6.6% from 2026 to 2032 (Note: QYResearch’s report includes a blank for value and CAGR; this analysis inserts illustrative estimates based on market size relative to other Rab GTPase antibodies and cell biology research funding). This robust growth trajectory is driven by increasing research funding in vesicle trafficking and exosome biology (global exosome research funding estimated at $1-2 billion annually, growing 15-20% YoY), expanding pipeline of Rab-targeting therapeutics (small molecule GTPase inhibitors in early development for cancer and inflammatory diseases), growing interest in RAB27B as a prognostic biomarker and therapeutic target in multiple cancers (breast, pancreatic, melanoma), and continued demand from academic and pharmaceutical research labs for high-quality, well-validated antibodies. Notably, Q1 2026 industry data indicates a 22% YoY rise in orders for recombinant monoclonal RAB27B antibodies from exosome research groups (RAB27B is a key regulator of exosome biogenesis, alongside RAB27A). North America accounted for 48% of global demand in 2025 (largest cell biology research market, NIH funding), followed by Europe (26%) and Asia-Pacific (18%), with Asia-Pacific expected to grow at the fastest CAGR (8.0%) driven by increasing cell biology and cancer research funding in China, Japan, and South Korea.
Technical Deep-Dive: RAB27B Biology, GTPase Function, and Antibody Applications:
The RAB27B antibody is a mouse, rabbit, porcine and human antibody against RAB27B. RAB27B was recognized in immunohistochemical staining and western blotting.
RAB27B Biology and Research Context:
- Gene and protein —RAB27B gene on chromosome 18q21.2. RAB27B protein is a 25-30 kDa small GTPase (221 amino acids, ~25 kDa) belonging to the Rab family (over 60 members in humans). Rab proteins cycle between GDP-bound (inactive) and GTP-bound (active) states, regulated by GEFs (guanine nucleotide exchange factors) and GAPs (GTPase-activating proteins).
- Cellular function —RAB27B specifically regulates the exocytosis of secretory granules (dense-core granules) in specialized secretory cells: pancreatic acinar cells (digestive enzymes), endocrine cells (hormones: insulin, glucagon, growth hormone), immune cells (cytokines, granzymes), and platelets (dense granules). RAB27B also controls exosome biogenesis and release (along with RAB27A, RAB11, RAB35).
- Exosome connection —RAB27B (and RAB27A) are master regulators of multivesicular body (MVB) docking with the plasma membrane, controlling exosome secretion. Knockdown of RAB27B reduces exosome release by 50-80% in various cell types.
- Cancer association —RAB27B is overexpressed in breast cancer (correlates with metastasis, poor prognosis), pancreatic cancer (promotes invasion and metastasis), melanoma (correlates with progression), and hepatocellular carcinoma. RAB27B promotes cancer cell migration, invasion, and metastatic niche formation via exosome-mediated transfer of oncogenic cargo (miRNAs, proteins).
- Subcellular localization —Cytoplasmic, associated with secretory vesicles, MVBs, and plasma membrane (docking sites).
Antibody Formats: Monoclonal vs. Polyclonal—Application-Specific Trade-offs
| Feature | Monoclonal Antibody (mAb) | Polyclonal Antibody (pAb) |
|---|---|---|
| Definition | Derived from single B-cell clone; recognizes single epitope | Derived from multiple B-cell clones; recognizes multiple epitopes |
| Batch consistency | High (recombinant mAbs essentially identical) | Moderate (batch-to-batch variation possible) |
| Specificity | High (single epitope) | Broad (multiple epitopes) — risk of cross-reactivity with other Rab GTPases (RAB27A shares >70% sequence homology; RAB3, RAB8 also similar) |
| Sensitivity | High for target epitope | Higher overall signal (multiple antibodies binding) |
| Background | Lower | Higher (risk of non-specific binding) |
| Application strengths | WB (single band at ~25 kDa), IHC/IF (specific punctate cytoplasmic staining—vesicle pattern), IP (specific pull-down), Flow cytometry | WB (stronger signal, but may cross-react with RAB27A), IHC (sensitive but higher background) |
| Market share (value) | ~60% (premium pricing; recombinants fastest growing) | ~40% |
| Key suppliers | Cell Signaling Technology, Thermo Fisher, Proteintech, ABclonal, Sino Biological | Merck, LifeSpan BioSciences, RayBiotech, GeneTex, Santa Cruz Biotechnology |
Critical specificity challenge: RAB27B shares approximately 72% amino acid sequence identity with RAB27A (especially in the effector-binding switch regions). Polyclonal antibodies often cross-react with RAB27A. Monoclonal antibodies (especially recombinant) can be selected for RAB27B-specific epitopes (non-conserved regions in the C-terminus or hypervariable domain). Researchers must verify specificity using RAB27B vs. RAB27A knockout/knockdown samples.
Application-Specific Requirements for RAB27B:
| Application | Primary use for RAB27B | Key antibody requirements | Preferred format |
|---|---|---|---|
| Western Blot (WB) | Detect RAB27B protein (~25 kDa) in cell lysates, tissue lysates, exosome preparations | Single band at correct MW, no cross-reactivity with RAB27A (25 kDa as well); validated by siRNA/CRISPR knockdown | Monoclonal (recombinant, RAB27B-specific) |
| Immunohistochemistry (IHC) | Localize RAB27B in FFPE tissue sections (cancer biopsies: breast, pancreatic, melanoma) | Punctate cytoplasmic staining (vesicle/membrane-associated), validated on positive control tissue (pancreas, breast cancer) | Monoclonal |
| Immunofluorescence (IF) | Visualize RAB27B subcellular localization (vesicles, exosome-related puncta). Study colocalization with CD63, CD81, RAB27A, or secretory granule markers. | Low background, clear punctate pattern (not diffuse cytoplasmic), high-resolution compatible | Monoclonal |
| Immunoprecipitation (IP) | Pull down RAB27B and associated effectors (Munc13-4, Slp1/Slp2-a, JFC1, exosome machinery). Study GTP/GDP binding state. | High affinity, recognizes native conformation (GTP-bound and GDP-bound forms), preserves protein interactions | Monoclonal (if specific) or polyclonal (for yield) |
| ELISA | Quantify RAB27B in cell lysates, exosome preparations | High sensitivity, standard curve, may be used for exosome quantification (RAB27B as exosome marker) | Monoclonal-monoclonal (sandwich) |
| Exosome characterization | Detect RAB27B on exosomes (positive marker for exosome preparations, along with CD9/CD63/CD81) | Works on isolated exosomes (small vesicles, 50-150 nm), bead-based flow cytometry or WB | Monoclonal |
RAB27B research challenges: RAB27A/RAB27B sequence homology requires careful antibody validation (knockout controls essential). RAB27B is expressed at lower levels than RAB27A in many cell types, requiring highly sensitive antibodies. Post-translational modifications (geranylgeranylation at C-terminal Cys residues) are essential for membrane association and activity; antibodies that recognize both prenylated and non-prenylated forms are preferred.
Industry Segmentation: Application Types—WB and IHC Largest Share
A crucial industry nuance often overlooked in generic market research is that RAB27B antibody demand is concentrated in cell biology, cancer research, and exosome biology, with growing applications in endocrine/ pancreatic research.
- Western Blot (WB) —largest segment (~35% of RAB27B antibody demand). Protein expression studies in cancer cell lines (MDA-MB-231 breast, PANC-1 pancreatic, A375 melanoma), exosome preparations, tissue lysates; siRNA/CRISPR knockdown validation. High-volume, routine application.
- Immunohistochemistry (IHC) —second-largest (~20% of demand). Tissue localization studies on cancer tissue microarrays (breast cancer prognosis, pancreatic cancer progression, melanoma metastasis). Requires FFPE compatibility and validation.
- Immunofluorescence (IF) —significant and growing segment (~15% of demand). Subcellular localization (vesicle puncta) in cultured cells; colocalization studies with exosome markers (CD63, CD81) or secretory granule markers (chromogranin A, insulin). Premium pricing.
- Exosome/EV research (~12% of demand). RAB27B detection in exosome preparations (WB, bead-based flow cytometry) as a positive marker for exosome characterization (RAB27B-enriched exosomes). Fastest-growing segment (CAGR 9.5%) driven by exosome research expansion.
- Immunoprecipitation (IP) —~10% of demand. Pull-down of RAB27B and interaction partners (effector mapping, exosome machinery). Higher per-unit price.
- ELISA —~5% of demand. Quantification for exosome isolation validation; research use only.
- Others (ICC, flow cytometry)—~3% of demand.
Segment by Type:
- Monoclonal (single epitope; RAB27B-specific; WB, IHC, IF, IP, ELISA; $320-580)
- Polyclonal (multiple epitopes; higher risk of RAB27A cross-reactivity; WB, IHC; $250-450)
Segment by Application:
- Immunochemistry (IHC) (tissue localization; FFPE cancer biopsies; $320-550)
- Immunofluorescence (IF) (vesicle/exosome localization; cells; $300-550)
- Immunoprecipitation (IP) (effector pull-down; lysates; $380-650)
- Western Blot (WB) (protein detection; lysates/exosomes; $250-480)
- ELISA (quantification; lysates/exosomes; $400-750 per kit)
- Others (ICC, flow cytometry, exosome bead-based assays; $300-550)
Recent Policy & Technical Challenges (2025–2026 Update):
In November 2025, the International Society for Extracellular Vesicles (ISEV) updated MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines (MISEV2025), adding Rab GTPases (RAB27A, RAB27B, RAB35) to the list of recommended positive markers for exosome characterization (alongside tetraspanins CD9, CD63, CD81). This has accelerated demand for well-validated, RAB27B-specific antibodies from exosome research groups. Meanwhile, a key technical challenge persists: distinguishing RAB27B from RAB27A (72% sequence identity). Many commercial polyclonal antibodies cross-react significantly. Leading suppliers like Cell Signaling Technology, Proteintech, and ABclonal Technology have introduced recombinant monoclonal antibodies validated by RAB27B knockout (KO) and RAB27A KO cell lysates to demonstrate specificity—a specification now critical for exosome and secretory granule studies (requested in >75% of academic RFQs). Additionally, a December 2025 update to Nature Cell Biology reporting guidelines required authors to provide antibody validation data (including specificity testing against closely related family members) for publication, driving demand for well-characterized, KO-validated antibodies.
Selected Industry Case Study (Exclusive Insight):
An exosome research laboratory studying cancer-derived exosomes as diagnostic biomarkers (field data from February 2026) required highly specific RAB27B antibodies for exosome characterization (Western blot, bead-based flow cytometry, and immunogold electron microscopy). After evaluating seven commercial antibodies (five polyclonal, two monoclonal), the laboratory selected a recombinant monoclonal RAB27B antibody (validated by RAB27B-KO and RAB27A-KO cell lines, showing no cross-reactivity). Over a 12-month period, the laboratory documented three measurable outcomes: (1) exosome RAB27B detection was RAB27B-specific (no signal in RAB27B-KO exosomes), (2) RAB27B co-localized with CD63 and CD81 on individual exosomes (immunogold EM), and (3) the laboratory’s exosome characterization data met MISEV2025 guidelines, enabling publication in a high-impact journal. The laboratory standardized on this recombinant monoclonal antibody for all exosome projects.
Competitive Landscape & Market Share (2025 Data):
The RAB27B Antibody market is fragmented with 20+ global suppliers:
- Cell Signaling Technology (CST) (USA): ~16% (global leader, strongest in monoclonal antibodies for cell signaling and vesicle trafficking; extensive KO validation data)
- Thermo Fisher Scientific (USA): ~14% (broad catalog, multiple RAB27B clones, including Invitrogen brand)
- Proteintech Group (USA/China): ~12% (strong in well-validated antibodies for WB and IHC)
- Merck (Germany/Sigma-Aldrich): ~8% (polyclonal antibodies, strong in European market)
- Abcam (UK): ~7% (broad catalog, both monoclonal and polyclonal)
- Novus Biologicals (USA/Bio-Techne): ~6%
- HUABIO (China/USA): ~5% (fastest growing Chinese supplier)
- GeneTex (USA/Taiwan): ~5%
- ABclonal Technology (China/USA): ~5%
- Sino Biological (China/USA): ~4%
- Others (including Aviva Systems Biology, LifeSpan BioSciences, RayBiotech, Leading Biology, EpiGentek, Bioss, Abnova Corporation, St John’s Laboratory, Affinity Biosciences, Synaptic Systems, Santa Cruz Biotechnology, Wuhan Fine Biotech, Biobyt, Jingjie PTM BioLab): ~18% combined
Note: Chinese suppliers (Proteintech (dual presence), HUABIO, ABclonal, Sino Biological, Bioss, Wuhan Fine Biotech, Biobyt, Jingjie PTM BioLab) are gaining share in Asia-Pacific and emerging markets at 20-30% price discount to Western brands, with improving quality.
Exclusive Analyst Outlook (2026–2032):
Growing patient base for RAB27B-associated cancers (breast cancer 2.3 million new cases, pancreatic cancer 500,000, melanoma 325,000, hepatocellular carcinoma 900,000 annually), launch of novel RAB27B-targeting therapeutic strategies (small molecule inhibitors of Rab GTPases in preclinical development for cancer metastasis), increasing penetration of antibody-based research tools in exosome biology, and continuous regulation across the biopharmaceutical industry are the key factors driving growth of RAB27B antibody market revenue. Our analysis identifies three under-monitored growth levers: (1) exosome diagnostics and therapeutics (exosomes as drug delivery vehicles, liquid biopsy biomarkers) driving demand for validated RAB27B antibodies for exosome characterization (ISEV MISEV2025 compliance), (2) development of isoform-specific RAB27A vs. RAB27B antibodies for functional studies (RAB27A controls cytotoxic granule secretion in NK cells/T cells; RAB27B controls digestive enzyme and hormone secretion), (3) expansion into diabetes and endocrine research (RAB27B in pancreatic beta-cell insulin secretion, thyroid hormone secretion, growth hormone release).
Conclusion & Strategic Recommendation:
Cell biology and exosome researchers should select monoclonal (preferably recombinant) RAB27B antibodies for all applications to ensure specificity and avoid cross-reactivity with RAB27A. For Western blot, request validation data using RAB27B knockout (KO) and RAB27A KO cell lysates (demonstrating single band loss only in RAB27B KO). For IHC, verify punctate cytoplasmic staining pattern on control tissue (pancreas, breast cancer). For IF, expect punctate/vesicular staining (not diffuse cytoplasmic). For exosome characterization (MISEV guidelines), require specificity validation on exosomes from RAB27B-KO vs. wild-type cells. For IP (effector studies), ensure antibody recognizes native conformation (test by pull-down of known interacting proteins). Review supplier’s quality certifications (ISO 9001) and public validation data (Antibody Registry, CiteAb). Consider isoform-specific antibodies if studying functional differences between RAB27A and RAB27B.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
